10-Q: Biotricity Inc. Reports Q1 2025 Results: Revenue Growth and Strategic Balance Sheet Simplification

Biotricity Inc. announced its first quarter 2025 results, highlighting revenue growth and strategic efforts to simplify the balance sheet through debt and equity conversions.

Summary

• Biotricity Inc. reported a 5.8% increase in revenue for the three months ended June 30, 2024, reaching $3.2 million compared to $3.0 million in the same period last year.
• Technology fee revenue grew by 8.9% to $3.0 million, while device sales contributed $185 thousand.
• The company's gross profit margin improved to 73.8% from 63.5% in the prior year's comparable quarter.
• Operating expenses decreased by 17.8% to $3.5 million, driven by a 15% reduction in selling, general, and administrative expenses.
• Research and development expenses decreased to $0.5 million from $0.7 million in the prior year.
• The company experienced a net loss attributable to common shareholders of $6.9 million, or $0.49 per share, primarily due to a $3.05 million deemed dividend expense related to preferred stock conversions.
• Biotricity converted $6.1 million of Series A Preferred Stock and $1.1 million in related accrued dividends into 8.9 million common shares.
• The company also converted $1.4 million of convertible notes into 1.3 million common shares and 287,802 shares to be issued.
• The company issued 1,000,413 common shares in settlement of $741,316 in accounts payable.
• The company issued 97,811 common shares for net proceeds of $125,227.
• The company issued 70,000 common shares for services received with a fair value of $53,480.
• The company's cash balance was $100,731 as of June 30, 2024, compared to $786,060 as of March 31, 2024.
• The company has a working capital deficiency of $16.5 million as of June 30, 2024.
• The company has an accumulated deficit of $134.4 million as of June 30, 2024.

Sentiment

Score: 4

Explanation: The document shows some positive trends in revenue growth and cost control, but the significant net loss, low cash balance, and working capital deficiency raise serious concerns about the company's financial health and ability to continue as a going concern. The delisting from Nasdaq is also a negative signal.

Positives

• Revenue increased by 5.8% year-over-year, indicating growth in the company's core business.
• Gross profit margin improved to 73.8%, suggesting better cost management and pricing strategies.
• Operating expenses decreased by 17.8%, demonstrating improved operational efficiency.
• The company successfully converted a significant amount of preferred stock and convertible notes into common shares, simplifying the capital structure.
• Technology fee revenue increased by 8.9%, indicating strong customer retention and recurring revenue streams.

Negatives

• The company reported a net loss attributable to common shareholders of $6.9 million, primarily due to a $3.05 million deemed dividend expense.
• The company has a working capital deficiency of $16.5 million, indicating potential liquidity challenges.
• The company's cash balance decreased significantly to $100,731 as of June 30, 2024.
• The company has an accumulated deficit of $134.4 million, reflecting historical losses.

Risks

• The company has a working capital deficiency and a low cash balance, raising concerns about its ability to fund operations.
• The company's accumulated deficit of $134.4 million indicates a history of losses and potential challenges in achieving profitability.
• The company may need to raise additional capital, which could dilute existing shareholders or be on unfavorable terms.
• The company's ability to continue as a going concern is dependent on securing additional funding.
• The company was delisted from the Nasdaq Capital Market due to not meeting the minimum market value requirement.

Future Outlook

The company anticipates continued revenue growth and improved liquidity through business development and additional financing. They expect to continue to devote significant resources on capital expenditures, research and development, marketing and sales. The company believes its existing cash, along with anticipated near-term financings, will be sufficient to meet its needs for the next twelve months from the filing date of this report. However, they will need to seek additional debt or equity capital to respond to business opportunities and challenges.

Management Comments

• Management focused its efforts on simplifying the Company balance sheet by converting preferred shares and convertible notes into common stock.
• Management uses non-GAAP measures such as EBITDA and Adjusted EBITDA to assess operations, removing the effect of one-time, non-cash items.
• Management considers the EBITDA and adjusted EBITDA measures for the three month period ended June 30, 2024, which improved by 18.9% and 49.8%, respectively, when compared to the corresponding prior year period, to be indicators of the Companys progress towards breakeven profitability as well as improvement towards operating cash-flow break-even.

Industry Context

The company operates in the remote patient monitoring market, which is experiencing growth due to the increasing importance of telemedicine and remote patient monitoring technologies. The company is focused on the diagnostic mobile cardiac telemetry market and is expanding into remote chronic care management solutions. The healthcare AI market is projected to grow significantly, and the company is leveraging its proprietary AI technology to enhance its offerings.

Comparison to Industry Standards

• Biotricity's gross margin of 73.8% is relatively high compared to some medical device companies, indicating a strong pricing strategy or cost control.
• The company's revenue growth of 5.8% is moderate, but the 8.9% growth in technology fees suggests a strong recurring revenue model.
• The company's operating expense reduction of 17.8% is significant and indicates a focus on efficiency.
• The company's net loss of $6.9 million is substantial, but the adjusted EBITDA loss of $1.06 million suggests that the underlying business is improving.
• The company's cash balance of $100,731 is very low, indicating a need for immediate financing.
• The company's working capital deficiency of $16.5 million is a significant concern and needs to be addressed.
• The company's delisting from the Nasdaq Capital Market is a negative event and may impact investor confidence.

Related Party Transactions

• Trade and other payables and accrued liabilities as at June 30, 2024 and March 31, 2024 included $ 246,058 and $ 837,945 , respectively, due to a shareholder, who is a director and executive of the Company.

Stakeholder Impact

• Shareholders may be concerned about the company's net loss, low cash balance, and delisting from Nasdaq.
• Employees may be concerned about the company's financial stability and future prospects.
• Customers may be concerned about the company's ability to continue providing its products and services.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to focus on revenue growth and improving liquidity.
• The company will seek additional debt or equity capital to fund operations and growth.
• The company will continue to develop and commercialize its product offerings.
• The company will continue to monitor and manage its operating expenses.

Key Dates

Keywords

remote patient monitoring, cardiac monitoring, medical technology, Bioflux, Biocore, Biocare, revenue growth, gross margin, operating expenses, convertible notes, preferred stock, common stock, EBITDA, AI, FDA